These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872 [TBL] [Abstract][Full Text] [Related]
5. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients. Lalive PH; Kantengwa S; Benkhoucha M; Juillard C; Chofflon M J Neuroimmunol; 2008 Jul; 197(2):147-51. PubMed ID: 18555540 [TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. Hong J; Zang YC; Hutton G; Rivera VM; Zhang JZ J Neuroimmunol; 2004 Jul; 152(1-2):126-39. PubMed ID: 15223245 [TBL] [Abstract][Full Text] [Related]
7. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480 [TBL] [Abstract][Full Text] [Related]
8. Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response. Hesse D; Krakauer M; Lund H; Søndergaard HB; Langkilde A; Ryder LP; Sorensen PS; Sellebjerg F Neurology; 2010 May; 74(18):1455-62. PubMed ID: 20439848 [TBL] [Abstract][Full Text] [Related]
9. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. Bernal F; Elias B; Hartung HP; Kieseier BC Mult Scler; 2009 Jun; 15(6):721-7. PubMed ID: 19383643 [TBL] [Abstract][Full Text] [Related]
10. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668 [TBL] [Abstract][Full Text] [Related]
11. The effect of season on cytokine expression in multiple sclerosis and healthy subjects. Stewart N; Taylor B; Ponsonby AL; Pittas F; van der Mei I; Woods G; Walters H J Neuroimmunol; 2007 Aug; 188(1-2):181-6. PubMed ID: 17628701 [TBL] [Abstract][Full Text] [Related]
12. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis. Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524 [TBL] [Abstract][Full Text] [Related]
13. Expression of TNF-alpha mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1A. Sarchielli P; Critelli A; Greco L; Sokola E; Floridi A; Gallai V Cytokine; 2001 Jun; 14(5):294-8. PubMed ID: 11444910 [TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients. Weinstock-Guttman B; Tamaño-Blanco M; Bhasi K; Zivadinov R; Ramanathan M J Neuroimmunol; 2007 Jan; 182(1-2):236-9. PubMed ID: 17126411 [TBL] [Abstract][Full Text] [Related]
15. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900 [TBL] [Abstract][Full Text] [Related]
16. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504 [TBL] [Abstract][Full Text] [Related]
17. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis. Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Bornstein NM; Karni A J Neuroimmunol; 2011 Mar; 232(1-2):171-8. PubMed ID: 21111488 [TBL] [Abstract][Full Text] [Related]
18. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. Iglesias AH; Camelo S; Hwang D; Villanueva R; Stephanopoulos G; Dangond F J Neuroimmunol; 2004 May; 150(1-2):163-77. PubMed ID: 15081262 [TBL] [Abstract][Full Text] [Related]
19. T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients. Satoh J; Nakanishi M; Koike F; Onoue H; Aranami T; Yamamoto T; Kawai M; Kikuchi S; Nomura K; Yokoyama K; Ota K; Saito T; Ohta M; Miyake S; Kanda T; Fukazawa T; Yamamura T J Neuroimmunol; 2006 May; 174(1-2):108-18. PubMed ID: 16564577 [TBL] [Abstract][Full Text] [Related]
20. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Boz C; Oger J; Gibbs E; Grossberg SE; Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]